Targeted delivery systems for oligonucleotide therapeutics. - Wikidata - wikimedia - TriplyDB

Targeted delivery systems for oligonucleotide therapeutics.

Targeted delivery systems for oligonucleotide therapeutics.

http://www.wikidata.org/entity/Q37417572

about

Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer.In vitro 3D model and miRNA drug delivery to target calcific aortic valve disease.High-density lipoproteins for the systemic delivery of short interfering RNA.Targeted gene silencing using a follicle-stimulating hormone peptide-conjugated nanoparticle system improves its specificity and efficacy in ovarian clear cell carcinoma in vitro.Topical delivery of siRNA into skin using SPACE-peptide carriers.In vivo delivery of cell-permeable antisense hypoxia-inducible factor 1α oligonucleotide to adipose tissue reduces adiposity in obese mice.Challenges in design and characterization of ligand-targeted drug delivery systems.Gold nanoparticles enhanced electroporation for mammalian cell transfection.Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.How nanotechnology can enhance docetaxel therapy.Polyplex-induced cytosolic nuclease activation leads to differential transgene expression.Microfluidic methods for production of liposomes Microfluidic assembly of lipid-based oligonucleotide nanoparticles In vivo delivery of miRNAs for cancer therapy: challenges and strategies.Size Specific Transfection to Mammalian Cells by Micropillar Array Electroporation.Cutaneous short-interfering RNA therapy.Receptor-targeted nanocarriers for therapeutic delivery to cancer.siRNA therapy for cancer and non-lethal diseases such as arthritis and osteoporosis.Action and reaction: the biological response to siRNA and its delivery vehicles.Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy.Chemical architecture and applications of nucleic acid derivatives containing 1,2,3-triazole functionalities synthesized via click chemistry.MicroRNAs in myeloid malignancies.Oligonucleotide conjugates for therapeutic applications.RNAi Therapeutics in Autoimmune Disease.Rational design of an immunoconjugate for selective knock-down of leukemia-specific E2A-PBX1 fusion gene expression in human Pre-B leukemia.Oligonucleotide therapeutics: chemistry, delivery and clinical progress.The Role of miRNAs in Angiogenesis, Invasion and Metabolism and Their Therapeutic Implications in Gliomas.Insight into mechanisms of cellular uptake of lipid nanoparticles and intracellular release of small RNAs.Gene delivery nanoparticles to modulate angiogenesis.Recent applications of the combination of mesoporous silica nanoparticles with nucleic acids: development of bioresponsive devices, carriers and sensors.Lipid nanoparticles for hepatic delivery of small interfering RNA.A secretagogue-small interfering RNA conjugate confers resistance to cytotoxicity in a cell model of Sjögren's syndrome.A novel murrel Channa striatus mitochondrial manganese superoxide dismutase: gene silencing, SOD activity, superoxide anion production and expression.A polyethylenimine-linoleic acid conjugate for antisense oligonucleotide delivery Iron Oxide Nanoparticles Coated with a Phosphorothioate Oligonucleotide and a Cationic Peptide: Exploring Four Different Ways of Surface Functionalization.Delivery of Antioxidant and Anti-inflammatory Agents for Tissue Engineered Vascular Grafts.High-performance method for specific effect on nucleic acids in cells using TiO2~DNA nanocomposites.Selection and Characterization of a DNA Aptamer Specifically Targeting Human HECT Ubiquitin Ligase WWP1.Selection and Identification of Skeletal-Muscle-Targeted RNA Aptamers.

P2860

Q28390007-9DDEF088-FA50-491A-869A-F8AA86B8040D Q33635355-AC857216-EE19-42D4-BEA3-ABBACC507DD7 Q33765102-524F371B-A32D-4C2F-B0DF-2C54AB54062D Q33786171-64EE2FB2-2938-42A8-88EB-12CA5C160911 Q34386258-BB9877A3-57B1-4BD0-B4A1-AB3E468F87F3 Q35587915-4B68BBCF-1249-4EE9-9FC2-E6BCF0F183DC Q36044388-EBC4DBC3-EFE7-4066-B4BF-6687C2F9F5A7 Q36346851-9C5AFE0D-0DC5-4A78-880E-2AD6726A2EC2 Q36417394-804BEEEC-6D00-4582-BB6B-34806B6A9E7A Q36512593-76E21A88-FD2C-46EC-8AC8-43BA34FEA4E7 Q37091683-7EBBC467-A008-46B2-BA83-0D463C924E13 Q37180506-FF1A2287-26B1-43C0-9E42-9057BD0FB927 Q37214585-05FB4D3F-2C09-427E-AA8D-CFB6C1DFDE21 Q37217266-57276DAD-871D-4E15-B8E4-F7D2D2FFA117 Q37228217-9C13664D-3CE7-4EE6-9617-C86788172B7A Q37479832-19CA2646-5011-431E-8B13-6F24203713DB Q37639312-9B788B88-3814-4151-A34F-3CE41FEE7DB4 Q37804383-B6069F72-5365-4C01-98A3-47D4FF7D0FCE Q37807993-718F3598-5EA3-43DF-98D0-18D98BF2A356 Q37976576-4848FE16-58AE-4146-85B9-A7E3945E8FF0 Q38037048-62B412A1-4F3D-42EC-BA1F-7F8DCF0B1083 Q38056000-B9D776E1-8958-4187-9AA1-14355DFEA9ED Q38107272-5CF4C192-780A-433A-BC4A-F66CBC9C7969 Q38123854-6872B6D6-6DBF-423B-891A-881D572DA1AF Q38166206-25762079-5E48-4D9E-BDB3-51F3839F21F1 Q38321588-85277D78-C19B-4542-A2E8-DC6FEEABF85B Q38618638-DFF33403-E138-4688-AFDD-9BA6E0D25253 Q38683271-A34B82ED-F575-4A45-9741-889109FAC9EC Q39003380-F3B1A4CD-91B8-4DC6-B16F-6D06C11685EF Q39027588-C8E1FAB1-F36B-4ED4-B902-FA5BF4A77FFF Q39096024-D48CEE23-8051-4FD8-AA4C-5C4CC0FAC49B Q39339170-8233D7C6-2DCA-43BE-B7BC-34C313532563 Q39543676-EF975499-58E6-4A81-809B-3A6553407A2D Q41756915-0173C4AE-6EDF-4586-8A9F-D477109F5BDE Q41876243-59F1E613-CA28-4F25-8D95-3C3B7D362451 Q42322021-DA5CA7A5-5475-45AF-83E6-71F1E95D1613 Q42369932-ECD2A5C1-39C2-4D30-ACBF-A3CF7067B173 Q42410857-FE90148D-4E63-4BFA-8FB4-84449412D895 Q52362632-F9E132F3-3794-4EF6-9A36-626A19EE8E4C Q52676614-D0C4AB97-156D-486E-A30F-C52CDEBA0A35

P2860

Targeted delivery systems for oligonucleotide therapeutics.

http://www.wikidata.org/entity/Q37417572

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeted delivery systems for oligonucleotide therapeutics.

@en

Targeted delivery systems for oligonucleotide therapeutics.

@nl

type

label

Targeted delivery systems for oligonucleotide therapeutics.

@en

Targeted delivery systems for oligonucleotide therapeutics.

@nl

prefLabel

Targeted delivery systems for oligonucleotide therapeutics.

@en

Targeted delivery systems for oligonucleotide therapeutics.

@nl

P1433

Q37417572-0A82BA10-8AB3-43FE-9F38-948BF5CAD13F

P1476

Q37417572-F3122FB5-BDBE-410C-9FB6-C8E8DE569B16

P2093

Q37417572-189C47DC-C3C0-454E-B1DC-6F9F62BDA4ED

Q37417572-741D32BB-444D-4C14-8A7B-CE2EB51B076C

Q37417572-A048D343-1CEF-440E-805D-AA78B1C013CB

Q37417572-D6ACC63A-E495-485A-BA5D-39D7FD805F6D

P2860

Q37417572-05850DBF-DEBD-4515-A868-9E15FB9841F8

Q37417572-0DBFB3EC-82A5-494A-901D-27032916B40C

Q37417572-0E22CD9B-04EA-47D4-80C3-E2A02367300B

Q37417572-181F6BA3-E1BD-4E77-9253-BAE3FF7808EA

Q37417572-18E62602-3F50-4D21-B9CD-AFE2593641C6

Q37417572-1C7DF3E3-1624-4224-A1C4-5F6257DCCED9

Q37417572-1CDE8B77-C90E-4EDD-A386-F29CED2F177D

Q37417572-1CF17C24-8A4C-4873-9AF7-105E39D5A736

Q37417572-1DD68B34-FF12-41CF-BE45-2B04D4342CE1

Q37417572-1E8287EC-4153-4DA4-9D16-4A6960E2A8C7

P2888

Q37417572-90955C91-E150-4E58-B096-1BDA2E93D7E6

P304

Q37417572-B87310BD-AA68-4852-A7AD-CBA27E17EC2C

P31

Q37417572-A33FDF30-1438-45DA-B23F-2FFDF6351B85

P356

Q37417572-1DAC4803-FB73-47F4-ABC7-03E8A3FCFDE7

P407

Q37417572-9094C5EF-FB2D-4B78-A0C9-0C6E5F9AD252

P433

Q37417572-25E0A575-C689-42DA-A307-CA3C6FFA0D90

P478

Q37417572-E3322C6C-1D12-45DB-B20C-62CAE87C5A32

P577

Q37417572-A3A3C758-6015-40F3-85AB-EF9CEE26B925

P5875

Q37417572-93E4BC84-6651-4B1B-9F6B-2035AF6FA4B7

P6179

Q37417572-4F57A7EB-A5EE-4BA3-B700-1FCE2905ABC0

P698

Q37417572-DCF78CDE-4882-4FFD-9D9C-C6C4E7F4D3ED

P932

Q37417572-B58DDF90-2123-4649-8F0B-0F4CDD381BAC

P356

S12248-009-9096-1

P1433

The AAPS Journal

P1476

Targeted delivery systems for oligonucleotide therapeutics.

@en

P2093

Bo Yu

http://www.w3.org/2001/XMLSchema#string

L James Lee

http://www.w3.org/2001/XMLSchema#string

Robert J Lee

http://www.w3.org/2001/XMLSchema#string

Xiaobin Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle

Fomivirsen approved for CMV retinitis

Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway

The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells

Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target

Progress towards in vivo use of siRNAs

Phage display of random peptide libraries: applications, limits, and potential.

Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides.

A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides.

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.

P2888

s12248-009-9096-1

P304

195-203

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1208/S12248-009-9096-1

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24210197

http://www.w3.org/2001/XMLSchema#string

P6179

1031120112

http://www.w3.org/2001/XMLSchema#string

P698

19296227

http://www.w3.org/2001/XMLSchema#string

P932

2664895

http://www.w3.org/2001/XMLSchema#string